中医学报Issue(10)：1400-1402,3.
生脉饮加味联合化疗治疗晚期非小细胞肺癌临床研究
Clinical Study of Modified Shengmai Yin Combination with Chemotherapy Treatment of Advanced Non-Small Cell Lung Cancer
摘要
Abstract
Objective:To analyze the clinical effect of Modified Shengmai Yin combination with chemotherapy treatment of elderly ad-vanced non-small cell lung cancer. Methods:136 cases of patients with elderly advanced non-small cell lung cancer were randomly di-vided into the experimental group and the control group. The control group received gemcitabine combined with cisplain,while the ex-perimental group based on the control group,received extra modified Shengmai Yin. The peripheral T cell subsets and cytokine levels of two groups were compared before and after treatment. The incidence of adverse reactions were compared during treatment. The clinical efficacy of two groups were compared 3 months after treatment. Results:CD3 + in both groups 3 months after treatment were significantly higher than before. CD3 + CD8 + ,NK,NKT and Treg levels in the experimental group 3 months after treatment were significantly higher than those before treatment,and CD3 + CD4 + was significantly lower than those before treatment. CD3 + CD4 + ,CD3 + CD8 + ,NK,NKT and Treg were significantly lower in the control group 3 months after treatment than those before treatment and the experimental group (P < 0. 01). IFN-γ,TNF-α,IL-2 levels in the experimental group were significantly increased 3 months after treatment;IFN-γ,TNF-α, IL-2 levels were significantly lower in the control group were significantly decreased 3 months after treatment,and the difference was sta-tistically significant(P < 0. 01). The effective rate of experimental group was 48. 53% and 38. 23% in the control group,and there was no significant difference. during Treatment,overall incidence of adverse reactions in the experimental group was 47. 06% ,less than 72. 05% of the control group,and the difference was statistically significant(P < 0. 01). Conclusion:Modified Shengmai Yin combined with chemotherapy in the treatment of advanced non-small cell lung cancer can not only improve the patients' level of immunity,but also reduce the incidence of adverse reactions.关键词
生脉饮/非小细胞肺癌/化疗Key words
shengmai yin/advanced non-small cell lung cancer/chemotherapy分类
医药卫生引用本文复制引用
陆烨,王晨洁,余蓉..生脉饮加味联合化疗治疗晚期非小细胞肺癌临床研究[J].中医学报,2014,(10):1400-1402,3.基金项目
江苏省教育厅科技进步人才项目 （）
